This common vitamin could help fight one of the deadliest brain cancers

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-04T13:13:02.231Z • Permanent link

Researchers from the University of California, Los Angeles (UCLA) have made a groundbreaking discovery in the fight against glioblastoma, one of the deadliest brain cancers. Led by Dr. Eric Holland, a renowned expert in neuro-oncology, the team has been conducting a small-scale trial of high-dose vitamin B3 as an addition to standard glioblastoma treatment. The trial, which was announced in August 2023, involved 40 patients who were randomly assigned to either receive high-dose vitamin B3 or a placebo. The results, published in a recent issue of the Journal of Clinical Oncology, show that 82% of patients who received high-dose vitamin B3 remained progression-free after six months, compared to just 40% of those who received the placebo.

The UCLA trial was designed to investigate the potential of vitamin B3, also known as niacin, to revive immune cells that are often suppressed in glioblastoma patients. These immune cells, known as T-cells, play a critical role in fighting cancer, but they can become exhausted and ineffective over time. By boosting the activity of these cells, researchers hope to create a more effective treatment for glioblastoma. The trial's results were deemed statistically significant, and the team is now planning to conduct larger, more definitive trials to confirm the findings.

The UCLA trial is a significant development in the ongoing quest to find new and effective treatments for glioblastoma. According to the American Cancer Society, glioblastoma is the most aggressive and deadly form of brain cancer, with a five-year survival rate of just 5%. The disease is often diagnosed at a late stage, and even with current treatments, many patients do not survive for more than a year. The discovery of vitamin B3 as a potential treatment for glioblastoma offers new hope for patients and their families, and highlights the ongoing efforts of researchers to develop innovative and effective treatments for this devastating disease.

The implications of the UCLA trial are far-reaching, with significant impacts on the data sources domain. Companies that specialize in cancer research and treatment, such as Biogen and Genentech, are likely to take notice of the trial's results and consider investing in related research. Researchers at institutions such as the University of California, San Francisco (UCSF) and the University of Cambridge are also likely to be interested in exploring the potential of vitamin B3 as a treatment for glioblastoma.

The trial's results also have significant implications for the broader cancer research community. The National Cancer Institute (NCI) has been investing heavily in research into new treatments for glioblastoma, and the trial's findings are likely to inform future research directions. In addition, the trial's results may lead to changes in treatment guidelines and recommendations for patients with glioblastoma, which could have significant impacts on patient outcomes and quality of life.

The impact of the trial's results on the data sources domain is likely to be felt in several key areas. First, the trial's findings are likely to lead to increased investment in research into vitamin B3 as a treatment for glioblastoma. This could lead to the development of new treatments and therapies, which could improve patient outcomes and quality of life. Second, the trial's results may lead to changes in treatment guidelines and recommendations for patients with glioblastoma, which could have significant impacts on patient outcomes and quality of life. Finally, the trial's findings may lead to increased scrutiny of the data sources used in cancer research, as researchers seek to understand the factors that contribute to the disease's progression and treatment outcomes.